LX 2931

Drug Profile

LX 2931

Alternative Names: LX 3305; LX2931

Latest Information Update: 25 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lexicon Pharmaceuticals
  • Developer CureDuchenne Ventures; Dermecular Therapeutics; Lexicon Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Immunosuppressants; Lymphocyte inhibitors; Sphingosine 1 phosphate lyase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Rheumatoid arthritis

Highest Development Phases

  • Phase II Rheumatoid arthritis
  • Phase I/II Skin disorders
  • No development reported Duchenne muscular dystrophy

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 28 May 2018 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in USA
  • 25 May 2018 Phase-I/II clinical trials in Skin disorders in France (PO) (EudraCT2018-000373-80)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top